Background/Objectives: The practice of palliative radiation therapy (RT) is based on extrapolation from adult literature. We evaluated patterns of pediatric palliative RT to describe regimens used to identify opportunity for future pediatric-specific clinical trials. Results: Of 3,225 pediatric patients, 365 (11%) were treated with palliative intent to a total of 427 disease sites. Anesthesia was required in 10% of patients. Treatment was delivered to metastatic disease in 54% of patients. Histologies included neuroblastoma (30%), osteosarcoma (18%), leukemia/lymphoma (12%), rhabdomyosarcoma (12%), medulloblastoma/ependymoma (12%), Ewing sarcoma (8%), and other (8%). Indications included pain (43%), intracranial symptoms (23%), respiratory compromise (14%), cord compression (8%), and abdominal distention (6%).
INTRODUCTION
Several studies have demonstrated the efficacy of palliative radiation therapy (RT) in the management of symptoms due to progressive primary or metastatic disease for adult oncology patients. [1] [2] [3] Indications in this setting include pain, cord compression, intracranial symptoms, respiratory distress, obstructive symptoms, and superior vena cava syndrome. Yet, similar data are sparse for the use of palliative RT in children with cancer, with little consensus regarding its application in the pediatric population. Current practices are based on extrapolations from the adult palliative RT literature; however, regimens should be scrutinized for their appropriateness for the pediatric population.
Pediatric patients suffer from a unique histologic profile of malignancies. Additionally, medical management of cancer-related symptoms such as pain often includes narcotic medications, which are used with more caution in children due to fear of side effects. It is thus imperative to investigate the specific indications, doses, and outcome of palliative RT in pediatric cancers.
Our study evaluates the practice patterns of pediatric palliative RT through an international pediatric research consortium to highlight the various indications for therapy and regimens employed. These data can be used to identify opportunities for future palliative RT clinical trials specific for pediatrics to address the paucity of data for the management of this patient population.
METHODS AND MATERIALS

Consortium participants
Pediatric radiation oncologists at eight international institutions with dedicated pediatric expertise participated in a research consortium to evaluate the clinical practice of palliative RT in patients ≤21 years old treated from January 2010 to December 2015. Palliative intent was defined as treatment with the goal to improve symptoms or to prevent impending symptoms such as in the case of intracranial or spine involvement. Participating institutions independently evaluated their palliative RT practice patterns for pediatric patients, and six institutions completed the survey based on their internal review. Two of the six institutions were equipped with proton RT capabilities.
Protocol and statistics
Radiation oncologists with expertise in pediatric malignancies were asked to complete a 122-item survey comprised of mixed rank order, constant sum, mixed dichotomous, multiple choice, or open-ended questions regarding individual practice of palliative RT. Surveys were collected and coded by a single physician affiliated with the consortium. The survey included 10 subjective questions on physician perceptions and attitudes regarding palliative RT for pediatric patients.
Subjective questions were answered on a Likert scale, with potential responses as "never," "rare," "sometimes," and "frequently." Responses were dichotomized, grouping "never" with "rarely" and "sometimes" with "frequently" for analysis and discussion. Descriptive statistics including means, medians, and frequencies were calculated using Excel software (Microsoft Corporation, Redmond, WA).
Measures
Treatment population characteristics
Consortium participants individually reviewed all respective pediatric cases at their institutions and identified specific pediatric palliative RT cases. Cases were totaled and reported based on age, histology, treatment location, and indication.
Radiation protocol
Patients were treated with palliative RT based on the individual practice pattern of each consortium institution. Technique, use of imageguidance, dose, and fractionation were employed at the discretion of the prescribing physician. 
RESULTS
Consortium treatment demographics
Palliative RT utilization
Details of anatomic sites receiving palliative RT across the international consortium institutions are reflected in Table 2 . Overall, the most common anatomic site treated was nonspine bone (n = 152, 35%). Primary brain lesions (n = 69, 16%) were the second most common site, followed by lesions in the abdomen/pelvis (n = 63, 15%), spine (n = 53, 12%), head and neck (n = 38, 9%), brain metastases (n = 24, 6%), lung (n = 23, 5%), liver (n = 3, 1%), and other cases (n = 3, 1%). When weighted across the institutions, nonspine bone (42%) and spine lesions (15%) were the two most common sites treated.
Malignant tumor histologies treated with palliative RT across consortium institutions are summarized in Table 3 Weighed percentage over six institutions, calculated using total patients per treatment intents (or lesion category or anesthesia required or age group) divided by 6, e.g., for palliative RT (11%
+ 1%)/6 = 11.3%.
Pain was the most common symptom requiring palliative RT across all consortium institutions, totaling 43% of all cases, followed by intracranial symptoms (23%), respiratory compromise (14%), cord compression (8%), abdominal distention (6%), bowel obstruction (3%), and postoperative spine (2%) ( Table 4) . Two cases falling into a unique "other" category reflect the use of palliative RT for cosmesis of a facial mass and a case of a mass encircling the aorta that was asymptomatic but posed a risk for an immediate life-threatening event. When cases were averaged across institution, pain and intracranial symptoms persisted as the most common indication necessitating palliative RT (57 and 16%, respectively).
Palliative RT delivery
Consortium participants reported frequent dose and fractionation regimens based on anatomic sites (Supplementary Table S1 ) and presenting symptoms (Supplementary Table S2 ) necessitating palliative RT.
Given the inherent radiosensitivity of leukemia/lymphomas, the palliative RT regimens for this particular histology are listed separately in Supplementary Table S1 .
The most common RT delivery technique was three-dimensional conformal RT (41%), followed by conventional RT (anterior-posteriorposterior-anterior, 26%), and intensity-modulated RT (23%) ( Table 5 ).
Stereotactic body radiation therapy (SBRT, 6%), electrons (1%), proton RT (1%), and other techniques (2%) were less frequently employed.
Weighted across institutions, the frequencies of RT techniques were similar (Table 5 ). SBRT and protons were primarily utilized for brain cases. Re-irradiation comprised 16% of cases. Palliative RT was delivered using cone beam computed tomography image guidance in 163 cases (41%). Table 6 reflects the responses of participating radiation oncologists regarding their impressions of potential factors limiting the ability to offer palliative RT. Concern for toxicity of treatment was reported as the most common concern regarding the utilization of palliative RT for pediatric patients, with five of six of radiation oncologists reporting referring provider's concern for acute or late toxicity being "sometimes" or "frequently" a barrier. The second most common barrier was logistics (i.e., time/travel away from home), reported as "sometimes" or "frequently" a barrier to palliative RT by four of six clinicians. Referring provider's willingness or other provider's awareness to consider palliative RT were each reported as "sometimes"
Clinician perspectives on pediatric palliative RT
or "frequently" barriers by two of six clinicians. Few clinicians felt that the availability of RT treatment resources, insurance authorization/cost, anesthesia availability, or parental concerns were a hindrance to palliative RT delivery. Four of the six clinicians reported that they offered palliative RT to >90% of their patients. Two other clinicians reported treating 33-66% and 66-90% of the patients, respectively. RT, radiation therapy; A&P, abdomen/pelvis; H&N, head and neck. a Weighed percentage over six institutions, calculated using total cases per anatomic site divided by 6, e.g., for nonspine bone (45% + 57% + 44% + 29% + 33% + 43%)/6 = 41.8%.
TA B L E 2 Anatomic site necessitating pediatric palliative RT by consortium institution
DISCUSSION
Our study describes the breadth of practice patterns of the use of palliative RT in pediatric oncology. We demonstrate frequent use across a variety of treatment sites and tumor types for various palliative indications. Further, we describe the most commonly utilized dose regimens and delivery techniques. Since the bulk of data on the use and technique of palliative RT is based on the experience and outcomes in adult oncology patients, our study is novel in that it provides data regarding practice patterns specifically for the pediatrics population across a consortium of international sites, including facilities with access to stereotactic and proton RT. Moreover, our study queries providers regarding potential factors limiting the ability to offer palliative RT.
Combined, these data offer unique insight to guide both future clinical trials and consensus statements regarding the use of palliative RT specific to the pediatrics population.
Defining the role of palliative RT and its optimal dose and fractionation schedules specific to this population is required to ensure safe and In our study, the reported "most common" regimen employed varied significantly across institutions for the same anatomic site and tumor histology. In clinical practice, the optimal total dose and fractionation of palliative RT is based on a number of factors including tumor histology, life expectancy of the patient and need for durable control, site of symptomatic disease, indication for treatment, and other patientspecific logistics including need for anesthesia and travel time to the facility. As such, the wide range of regimens reported is not surprising, although it does limit the ability for meaningful evaluation of safety and efficacy of specific regimens from this study.
The heterogeneity of treatment regimens used highlights the lack of consensus for optimal palliative management in pediatrics.
Whereas the safety and efficacy of a variety of dose and fractionations schedules are reported for palliative RT scenarios in adult patients, including brain metastases, 4-6 bone metastases, [7] [8] [9] and spinal cord compression, 10, 11 only few retrospective studies exist to describe the clinical experience of palliative RT in the pediatric population. Of these published retrospective studies, each report favorable rates of symptom improvement with palliative RT in pediatric patients. Bertsch et al.
reported on 91 courses of palliative RT for pediatric cancers. 12 Similar to our study, palliative RT represented 12% of the referrals during the study period. Clinical response rates of 55% in cord compression, 72% with respiratory compromise, 66% with intraabdominal tumors causing symptoms, 63% with intracranial symptoms, and 93% with pain were reported. Rahn et al. 13 Weighed percentage over six institutions, calculated using total patients per histology divided by 6, e.g., for neuroblastoma (12% Weighed percentage over six institutions, calculated using total patients per indication divided by 6, e.g., for pain (60%
TA B L E 4
= 56.8%. RT, radiation therapy; 3D-CRT, three-dimensional conformal radiation therapy; AP/PA, anterior-posterior-posterior-anterior; Electron, electron therapy; IMRT, intensity-modulated radiation therapy; Proton, proton therapy. a Weighed percentage over six institutions, calculated using total cases per indication divided by 6, e.g., for 3D-CRT (20% + 29% + 38% + 43% + 89% + 57%)/6 = 46%.
TA B L E 5 RT technique used for palliation
TA B L E 6
Radiation oncologists' conception of barriers to pediatric palliative With the existing data, the utility of palliative RT is promising.
Still, several of the consortium radiation oncologists cited referring provider's concern about toxicity, awareness of RT for palliation, or willingness to consider palliative RT as a barrier for its use in children. This was more commonly a barrier than anesthesia availability, treatment resource availability, cost or insurance authorization, or parental or patient concerns regarding RT. Thus, continued care for pediatric oncology patients in the multidisciplinary setting is imperative to ensure that all options, including palliative RT, are discussed with the patient.
Limitations of this study are primarily driven by the nature of this report as a survey of the participating institutions. This format limits the ability to report specific details of particular individual treatment regimens. In addition, these data do not attempt to assess response to therapy or toxicity to therapy. These are accepted limitations of this study by the authors, as this preliminary survey of practice patterns is intended to be a starting point for the design of future clinical trials across the pediatric consortium.
In conclusion, there is significant diversity of practice patterns in pediatric palliative RT. Research characterizing treatment response and toxicity is ongoing. Together, these data will inform the design of forthcoming clinical trials to establish effective regimens and minimize treatment time and toxicity.
